Birmingham

Horizontal Tabs

Treatment Modalities 
Surgery
Gene therapy
Biologics
Cell Therapy
Facilities/Translational Research 
Phase 1 Capability
  • First-in-Man studies, Multi-centre Phase 1 studies
  • Phase 1 population: Adult solid tumour and haematology
  • Phase 1 Mechanisms: Gene therapy, Immunotherapy, small molecules
  • Centre specific translational research interest: Gene and immunotherapy
Technology/equipment available within the centre
  • Provision of GMP-quality cellular products
  • Clinical grade selection of T cell by HLA-peptide tetramers
  • Laser capture microdissection
  • Microarray analysis
  • Proteomics
  • NMR facilities for metabolomics
Other Facilities
  • CTU; 6 exisiting research units
  • Cancer Research UK Institute for Cancer Studies (ICS)
  • Accredited Cancer Trials Unit by the National Cancer Research Institute
  • Cancer Research UK Key Centre for Early Phase Trials
  • Cancer Research UK Clinical Cancer Research Centre
  • NIHR/Wellcome Trust Clinical Research Facility
  • Centre for Clinical Haematology
  • Henry Wellcome Building for NMR Spectroscopy
  • Human Biomaterials Resource Centre

 

Sample collection

Contact for sample collection: Dr Jane Steele

 

 

ECMC funding provides infrastructure support for early phase and translational research.  From the ECMC Birmingham portfolio, the following trials have been carried out.

 
Trial activity between 2012-2015:

Trial by disease type between 2012-2015:

The Birmingham ECMC is supported by world class scientists, providing meaningful opportunities for collaborative engagement in the delivery of translational medicine in the research and treatment of cancer